← Mechanism / Class Hubs | Sibling class: BCMA × CD3 Bispecifics →
Last updated: June 16, 2026
A GPRC5D × CD3 bispecific is an antibody with two distinct binding arms. One arm binds GPRC5D (G-protein coupled receptor class C group 5 member D — an orphan G-protein coupled receptor highly expressed on plasma-cell-lineage tumor cells in multiple myeloma). The other arm binds CD3 on T cells. By tethering a T cell directly to a GPRC5D-expressing tumor cell, the bispecific redirects the patient's own immune system to attack the myeloma — an off-the-shelf, ready-now alternative to GPRC5D CAR-T (which is still in earlier clinical development).
Why GPRC5D? Before talquetamab, all approved CD3-engaging bispecifics in MM targeted BCMA. GPRC5D was the first non-BCMA target class to reach FDA approval, which matters clinically because patients whose disease progresses on a BCMA bispecific or BCMA CAR-T need a different target to respond. The trade-off is the distinctive side-effect signal: GPRC5D is expressed on plasma cells but also on keratinized tissues (taste buds, skin, hair, nails), so engaging T cells against GPRC5D produces on-target / off-tumor effects in those tissues — the patient-noticeable signal that distinguishes GPRC5D bispecifics from the BCMA class.
Administration. Talquetamab is given subcutaneously with cycle-1 step-up dosing (priming doses ramped to the full treatment dose) to mitigate cytokine release syndrome. The FDA label currently requires inpatient hospitalization for the step-up doses; outpatient administration is being tested (NCT05972135).
| Drug | Sponsor | Target | FDA Status | Administration |
|---|---|---|---|---|
| Talquetamab (Talvey, JNJ-64407564) | Janssen Biotech / Johnson & Johnson | GPRC5D × CD3 | Accelerated approval August 9, 2023 (4+ prior lines RRMM, post anti-CD38 + IMiD + PI) — readers should consult the current FDA prescribing information for the most up-to-date status | Subcutaneous, step-up dosing in cycle 1, inpatient required per label |
| JNJ-79635322 — BCMA × GPRC5D dual-bispecific, both single page-overlap and counted here | Janssen Biotech / Johnson & Johnson | BCMA × GPRC5D × CD3 (dual tumor-binding arms) | Not yet FDA-approved. Two Phase 3 trials open (NCT07518186 vs teclistamab; NCT07258511 vs anti-BCMA × CD3) | Subcutaneous, step-up dosing |
| SIM0500 — trispecific | Simcere | GPRC5D × BCMA × CD3 trispecific antibody | Not yet FDA-approved. Phase 1 (NCT06375044) | Per protocol (Phase 1 dose-finding) |
JNJ-79635322 dual-bispecific framing. JNJ-79635322 simultaneously engages both BCMA and GPRC5D on the tumor cell via two tumor-binding arms plus a CD3 arm — a dual-target strategy designed to reduce single-target antigen-escape resistance. We include it on both this GPRC5D hub and the BCMA hub because it engages both targets — the BCMA hub frames JNJ-79635322 as the BCMA-class next-generation comparator (teclistamab is the active comparator in NCT07518186); this GPRC5D hub frames JNJ-79635322 as a GPRC5D-engaging agent that adds GPRC5D engagement to BCMA. SIM0500 is similarly a tumor-cell-binding trispecific (GPRC5D + BCMA + CD3).
What about etentamig (ABBV-383)? Some sources have miscategorized etentamig as GPRC5D-targeted, but the AbbVie / Teneobio TNB-383B program is a BCMA × CD3 bispecific (not GPRC5D), and corpus-verified trial keywords list "B-Cell Maturation Antigen" as the target. Etentamig is covered on the BCMA bispecifics hub, not this page.
The only FDA-approved GPRC5D bispecific (accelerated approval August 9, 2023 on the MonumenTAL-1 dataset). Phase 3 trials include NCT06208150 (the 64407564MMY3009 / MonumenTAL-3-style design comparing Tal-P talquetamab + pomalidomide and Tal-Tec talquetamab + teclistamab vs EPd or PVd in RRMM after anti-CD38 + lenalidomide) and NCT05552222 (MajesTEC-7 family Tal-DR talquetamab + daratumumab + lenalidomide vs DRd in newly diagnosed transplant-ineligible MM). Subcutaneous administration. Distinctive dysgeusia / skin / nail signal — a dedicated Phase 2 trial (NCT06500884) is testing preventive treatments for GPRC5D-related oral events.
Full talquetamab page → (17 recruiting trials in detail)
Dual tumor-binding antibody simultaneously engaging both BCMA and GPRC5D on the tumor cell plus CD3 on T cells. Designed to reduce single-target antigen-escape resistance. Not yet FDA-approved. Two registrational Phase 3 trials are open: NCT07518186 (head-to-head vs teclistamab in RRMM after 1–3 prior lines — the first MM-bispecific Phase 3 using an approved bispecific as the active comparator) and NCT07258511 (vs an anti-BCMA × CD3 bispecific in RRMM). Phase 2 monotherapy expansion (NCT07266441), Phase 1 combination program with daratumumab +/− lenalidomide or pomalidomide (NCT06768489), Phase 1 RRMM + previously treated AL amyloidosis (NCT05652335), and MajesTEC-5 transplant-eligible NDMM (NCT05695508) included as JNJ-79635322-based arm.
5 unique JNJ-79635322 recruiting trials in the ClinTrialFinder corpus (June 2026) — counted separately from talquetamab.
Phase 1 first-in-human trispecific antibody simultaneously binding GPRC5D, BCMA, and CD3. Earlier-stage than JNJ-79635322 (also a dual-target approach but with three binding arms instead of three-arms-as-dual-bispecific). One recruiting Phase 1 (NCT06375044).
1 recruiting trial in the ClinTrialFinder corpus (June 2026).
Two single-center investigator-initiated Phase 2 trials use a GPRC5D/CD3 BiTE (bispecific T-cell engager) as maintenance after autologous stem cell transplant plus BCMA CAR-T therapy: NCT07106684 in transplant-eligible primary plasma cell leukemia and NCT07106710 in transplant-eligible ultra-high-risk multiple myeloma. NCT07185477 (not yet recruiting) is a single-center bridging trial using a GPRC5D/CD3 bispecific antibody before BCMA CAR-T in RRMM. The specific GPRC5D bispecific used in these protocols is not always specified in the brief title; readers should consult the ClinicalTrials.gov record for the protocol drug.
2 recruiting + 1 not-yet-recruiting investigator-initiated trial in the ClinTrialFinder corpus (June 2026).
The 25 recruiting GPRC5D-engaging bispecific trials below are grouped by the clinical setting most patients and hematologists ask about first — line of therapy + patient context. Each NCT links to ClinicalTrials.gov for current eligibility and study-site details. Most trials are talquetamab-anchored; JNJ-79635322 trials and the SIM0500 trispecific are pooled into the corresponding setting.
The defining GPRC5D Phase 3 wave — moving GPRC5D bispecifics into 1L+ RRMM and newly diagnosed MM, plus the first BCMA × GPRC5D dual-bispecific head-to-head:
The FDA-approved talquetamab setting (4+ prior lines, post anti-CD38 + PI + IMiD) and adjacent triple-class refractory combinations:
The strongest patient-actionable indication for GPRC5D bispecifics is after BCMA-directed therapy fails. Two dedicated GPRC5D-after-BCMA-CAR-T trials are recruiting:
The defining GPRC5D-bispecific side-effect signal is dysgeusia (taste loss) plus skin / nail / hair changes from on-target engagement in keratinized tissues. A dedicated Phase 2 trial is testing preventive treatments:
Two single-center protocols use a GPRC5D/CD3 BiTE as maintenance after autologous transplant + BCMA CAR-T:
Showing 25 recruiting interventional GPRC5D × CD3 bispecific trials — 17 talquetamab + 5 JNJ-79635322 (BCMA × GPRC5D dual-bispecific) + 1 SIM0500 (GPRC5D-BCMA-CD3 trispecific) + 2 investigator-initiated GPRC5D/CD3 BiTE maintenance — plus 1 not-yet-recruiting in the ClinTrialFinder corpus as of June 16, 2026. The talquetamab refractory generalized myasthenia gravis study (NCT07499323) is omitted from this oncology-focused page. The MM-relevant subset of the GPRC5D landscape excludes GPRC5D-targeting agents in other modalities (CAR-T, ADC, ADCC-enhanced monoclonal antibody) — those are tracked separately. For the latest searches: talquetamab, JNJ-79635322, GPRC5D bispecific.
GPRC5D × CD3 is the first non-BCMA CD3-engaging bispecific class approved in MM, but it is not the only option. Three plasma-cell-restricted CD3 bispecific target classes are in clinical use or late-stage development:
| Target | Approved Drugs | Distinctive Side Effects | Where it fits |
|---|---|---|---|
| BCMA × CD3 | Teclistamab (Tecvayli), elranatamab (Elrexfio), linvoseltamab (Lynozyfic) — see BCMA hub | Severe infections + hypogammaglobulinemia (IVIG replacement typically required); class-shared CRS, ICANS, cytopenias | 4L+ R/R MM (approved); earlier-line and front-line moves in progress via MajesTEC-7 / MagnetisMM-32 / LINKER-MM-3 / ELDORADO |
| GPRC5D × CD3 (this page) | Talquetamab (Talvey) | Dysgeusia, skin / nail / hair changes from keratinized-tissue expression; lower infection burden than BCMA; class-shared CRS, ICANS, cytopenias | 4L+ R/R MM (approved); post-BCMA sequencing is the strongest patient-actionable use case — the alternative when BCMA bispecific or BCMA CAR-T fails |
| BCMA × GPRC5D × CD3 (dual-target) | None approved — JNJ-79635322 in Phase 3 (NCT07518186 vs teclistamab; NCT07258511); SIM0500 trispecific in Phase 1 (NCT06375044) | Phase 3 safety data still maturing; expected to share the CD3-engaging class signal with both BCMA and GPRC5D on-target tissue effects in parallel | Emerging next-generation strategy — designed to reduce single-target antigen-escape resistance |
| FcRH5 × CD3 | None approved — cevostamab in Phase 3 (NCT07555938); see BCMA hub for the cevostamab section | CRS class signal; less broad normal-tissue footprint than BCMA; pivotal datasets still maturing | Emerging third target class — complementary sequencing option to BCMA and GPRC5D |
Cross-trial efficacy comparisons between talquetamab and the three approved BCMA bispecifics — or between GPRC5D, BCMA, and FcRH5 — have not been validated in head-to-head randomized trials and should not be inferred from response-rate differences across separate single-arm studies. The first head-to-head Phase 3 (NCT07518186) is currently asking whether the BCMA × GPRC5D dual-bispecific JNJ-79635322 beats single-BCMA-targeted teclistamab. The choice of which bispecific or which target class is right for a specific patient is a discussion with the patient's hematologist.
GPRC5D bispecifics share the broader CD3-engaging bispecific class profile (CRS, ICANS, cytopenias) but carry a GPRC5D-specific signal that distinguishes them from the BCMA class — reflecting where GPRC5D is normally expressed (plasma cells plus keratinized tissues):
By contrast, the BCMA bispecific class (teclistamab, elranatamab, linvoseltamab) has its defining signal in severe infection risk driven by hypogammaglobulinemia — requiring prophylactic antimicrobials and IVIG replacement throughout treatment. The framing that captures this most cleanly is GPRC5D = livable but distinctive keratinized-tissue effects; BCMA = life-threatening but manageable infection burden. Neither is universally "better"; the choice depends on the patient's situation and prior treatments.
What is GPRC5D × CD3 bispecific therapy and how is it different from BCMA bispecifics?
A GPRC5D × CD3 bispecific is an antibody with two binding arms. One arm binds GPRC5D (G-protein coupled receptor class C group 5 member D) — an orphan GPCR highly expressed on plasma-cell-lineage tumor cells in multiple myeloma — and the other arm binds CD3 on T cells, redirecting the patient's own T cells to kill GPRC5D-expressing myeloma cells. The key difference from BCMA bispecifics is the target: BCMA is highly expressed on normal plasma cells, so engaging BCMA depletes the patient's antibody-producing plasma cells and drives a sustained risk of severe infection from hypogammaglobulinemia. GPRC5D is expressed on plasma cells plus normal keratinized tissues (taste buds, skin, hair, nails), so the patient-noticeable signal shifts to dysgeusia, skin / nail / hair changes — distinctive and quality-of-life-affecting, but generally not life-threatening the way BCMA-driven infections can be. The GPRC5D class is therefore a key sequencing option for patients who progress on BCMA-directed therapy.
Which GPRC5D drug is FDA-approved and which trials am I eligible for?
Talquetamab (Talvey, JNJ-64407564, Janssen) is the only FDA-approved GPRC5D × CD3 bispecific as of June 2026 (accelerated approval August 9, 2023 for adults with R/R MM who have received at least 4 prior lines including an anti-CD38 antibody, a PI, and an IMiD). Other GPRC5D-engaging agents are in earlier clinical development: JNJ-79635322 (BCMA × GPRC5D dual-bispecific from Janssen) is in Phase 3 head-to-head against teclistamab (NCT07518186) and against an anti-BCMA × CD3 bispecific (NCT07258511); SIM0500 (Simcere, GPRC5D-BCMA-CD3 trispecific) is in Phase 1 (NCT06375044); and two investigator-initiated GPRC5D/CD3 BiTE maintenance trials are open in primary plasma cell leukemia (NCT07106684) and ultra-high-risk MM (NCT07106710). Eligibility depends on line of therapy, prior anti-CD38 / PI / IMiD / BCMA exposure, and trial-specific criteria.
What are the side effects I should expect (dysgeusia, skin, nails)?
The defining GPRC5D-bispecific signal reflects on-target / off-tumor effects in keratinized tissues, where GPRC5D is normally expressed. The most patient-noticeable side effects are dysgeusia (taste alteration or taste loss, often common and sometimes severe enough to affect oral intake and lead to weight loss), skin changes (rash, dryness, palmar-plantar exfoliation), nail changes (onycholysis, ridging, brittleness), and hair changes (alopecia or thinning). A dedicated Phase 2 trial (NCT06500884) is testing preventive treatments for talquetamab-related oral / dysgeusia events. Like all CD3-engaging bispecifics, GPRC5D bispecifics also carry CRS (mostly Grade 1–2, cycle-1, managed with tocilizumab), ICANS (less common, generally reversible), and cytopenias. Importantly, the infection / hypogammaglobulinemia burden is generally less prominent than with BCMA bispecifics because GPRC5D does not deplete normal antibody-producing plasma cells the way BCMA does.
Should I try BCMA or GPRC5D first, or in sequence?
There is no published randomized head-to-head trial comparing BCMA vs GPRC5D bispecifics as first-bispecific in MM — the choice is a discussion with your hematologist. Practical patterns: BCMA bispecifics (three FDA-approved drugs, larger pivotal-trial dataset) are often the first bispecific used. GPRC5D (talquetamab, one FDA-approved drug) is the key non-BCMA sequencing option when BCMA bispecific or BCMA CAR-T (ide-cel, cilta-cel) fails — the post-BCMA setting is where GPRC5D has the strongest patient-actionable indication (NCT06066346 talquetamab consolidation after BCMA CAR-T; NCT07093554 talquetamab bridging before cilta-cel BCMA CAR-T). In newly diagnosed and earlier-line settings, the choice is increasingly trial-defined: NCT05552222 (MajesTEC-7) directly compares Tec-DR (BCMA induction) vs Tal-DR (GPRC5D induction) vs DRd in the same trial; NCT07518186 and NCT07258511 are JNJ-79635322 (BCMA × GPRC5D dual-bispecific) Phase 3 trials asking whether dual-target beats single-target.
How do I get matched to a GPRC5D bispecific clinical trial?
Use ClinTrialFinder's AI-powered matching to surface GPRC5D bispecific trials based on your specific situation — line of therapy, prior anti-CD38 / PI / IMiD exposure, transplant status, prior BCMA bispecific or BCMA CAR-T exposure (the most relevant differentiator for GPRC5D trials, since post-BCMA sequencing is the strongest use case), and disease stage. Use the patient-match button below; the wizard routes through talquetamab as the most-established GPRC5D bispecific entry point and will surface relevant JNJ-79635322 and other GPRC5D-engaging trials in the same setting. For the alternative bispecific class, see our BCMA × CD3 Bispecifics Hub.
Find Matching GPRC5D Bispecific Trials
Use ClinTrialFinder's AI-powered matching to find talquetamab, JNJ-79635322, and other GPRC5D-engaging bispecific trials based on your line of therapy, prior BCMA exposure, and disease stage.
Find Matching GPRC5D Bispecific TrialsThis page is for information only and is not medical advice. ClinTrialFinder helps you find clinical trials that may match your situation, but enrollment decisions and treatment choices should always be made with your oncologist or hematologist. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here. FDA approval dates and indications are summarized for context only; consult the current FDA prescribing information for each drug for authoritative regulatory status.